TMC
ADAP

Trellus Management Company’s Adaptimmune Therapeutics ADAP Stock Holding History

Trellus Management Company’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-16,464
Closed -$195K – 63
2018
Q2 		$195K Buy
+16,464
New +$205K 0.29% 53
2018
Q1 		– Sell
-24,485
Closed -$164K – 65
2017
Q4 		$164K Buy
+24,485
New +$189K 0.22% 67

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Trellus Management Company's ADAP Position: Q3 2018 in Review

Trellus Management Company sold out of Adaptimmune Therapeutics (ADAP) in Q3 2018, closing a stake of 16,464 shares — an estimated $195K sold.

Trellus Management Company first reported a position in ADAP in Q4 2017 and held it in 2 quarters. The position peaked at $195K in Q2 2018. 93 funds tracked by Wall St. Rank hold ADAP as of Q3 2018.

  • Trellus Management Company reported no remaining Adaptimmune Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Trellus Management Company sold 16,464 Adaptimmune Therapeutics shares in Q3 2018, an estimated $195K.
  • Trellus Management Company first reported a position in Adaptimmune Therapeutics in Q4 2017 and held it in 2 quarters.
  • Trellus Management Company's Adaptimmune Therapeutics position peaked at $195K in Q2 2018.
  • 93 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q3 2018.

Based on Trellus Management Company's 13F filing for Q3 2018, filed 5 Nov 2018.